Showing 5211-5220 of 8889 results for "".
- DELTA FORCE: Delgocitinib Cream Superior for Chronic Hand Eczema Treatmenthttps://practicaldermatology.com/news/delta-force-delgocitinib-cream-superior-chronic-hand-eczema-treatment/2468306/New data from the DELTA FORCE trial presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress suggests that delgocitinib cream showed superior efficacy and safety compared to oral alitretinoin for the treatment of chronic hand eczema (CHE). “The completion of th
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan
- LEO Pharma Set for Five Late-Breaking Presentations at EADVhttps://practicaldermatology.com/news/leo-pharma-set-five-late-breaking-presentations-eadv/2468299/LEO Pharma A/S will present new clinical and real-world data from across its portfolio of products at the 33rd European Academy of Dermatology and Venereology (EADV) Congress from September 25-28 in Amsterdam, Netherlands, the company announced. Five coveted late-breaking presentations wi
- Roflumilast Cream Shows Consistent Results in AD Across Skin Typeshttps://practicaldermatology.com/news/roflumilast-cream-shows-consistent-results-ad-across-skin-types/2468298/Newly published pooled analyses of the INTEGUMENT trials suggest that ZORYVE (roflumilast) cream 0.15% showed significant improvements in atopic dermatitis (AD) symptoms, regardless of race, ethnicity, or Fitzpatrick skin type. Results from the studies showed that higher percentages of pat
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- Tirbanibulin Research for Actinic Keratosis to be Presented at EADVhttps://practicaldermatology.com/news/tirbanibulin-research-actinic-keratosis-be-presented-eadv/2468262/Almirall will present eight abstracts detailing the latest research on tirbanibulin for actinic keratosis at the 33rd Congress of the European Academy of Dermatology and Venereology (EADV), the company announced. The EADV takes place September 25-28 in Amsterdam, Netherlands. Almira
- sNDA Accepted for Roflumilast Foam 0.3% for Psoriasishttps://practicaldermatology.com/news/snda-accepted-roflumilast-foam-03-psoriasis/2468261/The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for roflumilast foam 0.3%—a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor branded ZORYVE by Arcutis Biotherapeutics, Inc.—for the treatment of adults and adolescents ages 12 and ov
- Researchers Analyze Social Media Posts on JAK Inhibitorshttps://practicaldermatology.com/news/researchers-analyze-social-media-posts-jak-inhibitors/2468227/An analysis of social media posts concluded that patients are most concerned about the efficacy and side effects of JAK inhibitors and issues regarding access to them, according to a new Archive of Dermatological Research article by members of the University of Nebraska Medical Center’s Departmen
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released